Dorchester Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Dorchester Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-90,705	Closed	-$3.01M	–	113
2017 Q2	$3.01M	Sell	90,705 -515	-0.6%	-$15.9K	1.04%	32
2017 Q1	$2.93M	Buy	91,220 +10,680	+13%	+$364K	1.02%	31
2016 Q4	$2.92M	Buy	80,540 +10,870	+16%	+$434K	1.06%	32
2016 Q3	$3.21M	Buy	69,670 +1,920	+3%	+$100K	1.19%	29
2016 Q2	$3.4M	Buy	67,750 +11,045	+19%	+$588K	1.26%	28
2016 Q1	$3.03M	Buy	56,705 +1,555	+3%	+$91.2K	1.15%	33
2015 Q4	$3.62M	Buy	55,150 +455	+0.8%	+$28.1K	1.5%	25
2015 Q3	$4.12M	Sell	54,695 -490	-0.9%	-$31.8K	1.52%	27
2015 Q2	$4.07M	Buy	+55,185	New	+$3.4M	1.34%	26

Other funds holding TEVA

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Dorchester Wealth Management's TEVA Position: Q3 2017 in Review

Dorchester Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 90,705 shares — an estimated $3.01M sold.

Dorchester Wealth Management first reported a position in TEVA in Q2 2015 and held it in 9 quarters. The position peaked at $4.12M in Q3 2015. 537 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Dorchester Wealth Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Dorchester Wealth Management sold 90,705 Teva Pharmaceuticals shares in Q3 2017, an estimated $3.01M.
Dorchester Wealth Management first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 9 quarters.
Dorchester Wealth Management's Teva Pharmaceuticals position peaked at $4.12M in Q3 2015.
537 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Dorchester Wealth Management's 13F filing for Q3 2017, filed 19 Oct 2017.